Nakamura, Yoshiaki
Kawazoe, Akihito
Lordick, Florian
Janjigian, Yelena Y.
Shitara, Kohei http://orcid.org/0000-0001-5196-3630
Article History
Accepted: 22 February 2021
First Online: 31 March 2021
Competing interests
: Y.N. has received research funding from Chugai Pharmaceutical, Genomedia, Guardant Health and Taiho Pharmaceutical. A.K. has received research funding from MSD, Ono, Sumitomo Dainippon and Taiho, and honoraria from Ono and Taiho. F.L. has received research funding from BMS, Iomedico and Zymeworks, and honoraria from Amgen, Astellas Pharma, AstraZeneca, Bayer, BioNTech, BMS, Eli Lilly, Elsevier, Excerpta Medica, Imedex, Infomedica, Iomedico, Medscape, MedUpdate, Merck Serono, MSD, Oncovis, Promedicis, Roche, SpringerNature, StreamedUp! and Zymeworks. Y.Y.J. has received institutional research funding from Bayer, Boehringer Ingelheim, BMS, Eli Lilly, Genentech/Roche, Merck and Roche, has acted as an advisor for AstraZeneca, Basilea Pharmaceutica, Bayer, BMS, Daiichi-Sankyo, Eli Lilly, Imugene, Merck, Merck Serono, Pfizer, Rgenix and Zymeworks, and holds stock options in Rgenix. K.S. has received research funding from Astellas, Chugai, Daiichi Sankyo, Eli Lilly, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Taiho, Medi Science and MSD, has acted as a consultant or advisor for AbbVie, Astellas, BMS, Eli Lilly, GSK, MSD, Novartis, Ono Pharmaceutical, Pfizer, Taiho and Takeda, and has received honoraria from AbbVie, Novartis and Yakult.